원문정보
초록
영어
Cell transplantation to repair or regenerate injured myocardium is a new frontier in the treatment of cardiovascular disease. Most studies on stem cell transplantation therapy in both experimental heart infarct and clinical trials have focused on the use of undifferentiated stem cells. Based on our previous studies demonstrating the multipotency of human periosteum-derived progenitor cells (PDPCs), we investigated the capacity of these cells to differentiate into
cardiomyocytes in this study. PDPCs were identified by the expression of many molecules including CD105 (SH2) and CD73 (SH3/4), and were negative for the hematopoietic markers CD34, CD45 and CD14. Differentiation of PDPCs into cardiomyocyte were induced with 5-azacytidine for 24 hours. Then the cells were incubated with TGF-β1 and IGF1 in maintenance media. After 5 weeks, induced PDPCs were analyzed by morphological observation and histological staining. The expression of cardiomyocyte-specific mRNA such as GATA-4,
Nkx2.5 was verified by RT-PCR analysis. These results suggest that the formation of cardiomyocytes from PDPCs by 5-azacytidine treatment provides a usable model for the study of cardiomyocyte differentiation.